Neurocrine Biosciences
NBIX
#1372
Rank
NZ$28.19 B
Marketcap
NZ$278.54
Share price
-2.25%
Change (1 day)
13.27%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): NZ$12.20

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is NZ$12.68. In 2025 the company made an earnings per share (EPS) of NZ$8.77 an increase over its 2024 EPS that were of NZ$6.15.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$12.2039.13%
2025NZ$8.7742.6%
2024NZ$6.1533.07%
2023NZ$4.6257.76%
2022NZ$2.9369.47%
2021NZ$1.73-78.21%
2020NZ$7.93990%
2019NZ$0.7381.82%
2018NZ$0.40-113.5%
2017NZ-$2.970.62%
2016NZ-$2.9557.28%
2015NZ-$1.8725.61%
2014NZ-$1.4918.84%
2013NZ-$1.26-1085.71%
2012NZ$0.13

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$1.29-89.81%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$10.65-16.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$56.22 343.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ-$0.36-102.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ-$3.69-129.12%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$9.43-25.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
NZ-$13.74-208.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$2.78-78.06%๐Ÿ‡ฌ๐Ÿ‡ง UK